União Europeia - português - EMA (European Medicines Agency)

torbet laboratories ireland limited - urea (13c) - breath tests; helicobacter infections - agentes de diagnóstico - este medicamento é apenas para uso diagnóstico. no vivo diagnóstico de intussuscepção helicobacter pylori (h. pylori) infecção.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

mundipharma brasil produtos mÉdicos e farmacÊuticos ltda - maleato de timolol - antiglaucomatosos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

organon farmacÊutica ltda. - antiglaucomatosos

União Europeia - português - EMA (European Medicines Agency)

nova laboratories ireland limited - espironolactona - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 e 5.

União Europeia - português - EMA (European Medicines Agency)

nova laboratories ireland limited - hidroxicarbamida - anemia, célula falciforme - agentes antineoplásicos - prevenção de vaso-oclusiva complicações da doença falciforme em pacientes com mais de 2 anos de idade.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ipsen portugal - produtos farmacêuticos, s.a. - triptorrelina - pó e veículo para suspensão injetável - 11.25 mg/2 ml - triptorrelina, pamoato 15 mg - triptorelin - n/a - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ipsen portugal - produtos farmacêuticos, s.a. - triptorrelina - pó e veículo para suspensão injetável - 22.5 mg/2 ml - triptorrelina, pamoato 31 mg - triptorelin - n/a - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ipsen portugal - produtos farmacêuticos, s.a. - triptorrelina - pó e solvente para solução injetável - 0.1 mg/ml - triptorrelina, acetato 0.1 mg - triptorelin - n/a - duração do tratamento: longa duração

União Europeia - português - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - mieloma múltiplo - agentes antineoplásicos - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

União Europeia - português - EMA (European Medicines Agency)

taw pharma (ireland) limited - cloridrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.